You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Article Text

Article menu

See original article:

Download PDFPDF

XML
Correction
Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

https://doi.org/10.1136/jitc-2020-000798corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer 2020;8:e000798. doi: 10.1136/jitc-2020-000798.

    Since the online publication of this article, the authors have noticed that in figure 4 the dotted and full lines were mislabelled. Please see the corrected Figure below:

    Figure 4
    Figure 4